title: Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia.
authors.affiliation: Department of Medicine Section of Cardiovascular Medicine, Yale University School of Medicine New Haven CT, USA.
authors.forename: Lawrence H
authors.initials: LH
authors.lastname: Young
authors.forename: Katharine J
authors.initials: KJ
authors.lastname: Henderson
authors.forename: Robert I
authors.initials: RI
authors.lastname: White
authors.forename: Guadalupe
authors.initials: G
authors.lastname: Garcia-Tsao
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001165:Arteriovenous Malformations / Q000209:etiology*; D002302:Cardiac Output / Q000187:drug effects*; D005260:Female; D006801:Humans; D008099:Liver / Q000098:blood supply*; D008297:Male; D013683:Telangiectasia, Hereditary Hemorrhagic / Q000188:drug therapy* / Q000503:physiopathology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized